4.0
Tilray Inc. is a healthcare-sector company operating within the cannabis and cannabinoid-based products industry, focused on the development, cultivation, processing, and distribution of medical cannabis and related products.
Founded in 2013 in Canada, the company was established to meet the growing demand for regulated medical cannabis during a period of significant legislative expansion in the country.
Tilray’s portfolio includes oils, capsules, dried flower, standardized extracts, pharmaceutical products, wellness items, and adult-use cannabis products in markets where such use is legal.
The company also operates in the beverages, hemp-based food, and CBD product segments, broadening its reach into multiple consumer categories.
Tilray has a global presence, with operations across North America, Europe, Australia, and Latin America. Its products are distributed through pharmacies, clinics, authorized distributors, and adult-use retail channels in regulated markets.
The company maintains research facilities, cultivation sites, and processing centers in several countries.
Market drivers for Tilray include regulatory changes, rising demand for cannabis-based therapies, scientific developments in cannabinoid research, and the global expansion of adult-use legalization. Tilray competes with other major cannabis companies such as Canopy Growth and Aurora Cannabis.
Its operational structure includes indoor and greenhouse cultivation units, pharmaceutical laboratories, distribution centers, and specialized teams in clinical research, regulatory compliance, and plant biotechnology.
Through a vertically integrated model, the company ensures quality and traceability throughout the entire production chain.
Tilray Inc. shares are traded on the Nasdaq under the ticker TLRY.
History and when Tilray Inc. was founded
Tilray Inc. was founded in 2013 in Nanaimo, British Columbia, Canada, becoming one of the first companies licensed by the Canadian government to produce medical cannabis.
In its early years, it focused on building production infrastructure and conducting clinical research, forming partnerships with universities and scientific institutions.
International expansion began in the mid-2010s, with exports to Europe and the establishment of operational units in Portugal and Germany, securing regulatory approvals for research and medicinal distribution.
In 2018, Tilray completed its initial public offering (IPO) on the Nasdaq, becoming the first cannabis company to IPO on a major U.S. exchange.
In 2021, Tilray merged with Aphria, creating one of the largest global cannabis companies. The merger expanded production capacity, product offerings, and market presence across North America, Europe, and other international regions.
Between 2020 and 2024, the company increased its participation in adjacent segments such as cannabis-infused beverages, traditional alcoholic beverages, hemp-based foods, and health and wellness products.
This period also included consolidation strategies, brand acquisitions, and the strengthening of international partnerships as global regulations continued to evolve.
Additional Information
The Company Tilray Inc. (United States), is listed on Nasdaq with a market value of $ 820.60 Millions, having an equity of $ 1.55 Billion.
With a total of 2.100 employees, the company is listed in the sector of Health and categorized in industry of Pharmaceutical Products.
In the last 12 months the Company had a revenue of $ 837.32 Millions, which generated a loss in the amount of $ -2.11 Billions.
As for its main indicators, the Company has a P/E ratio of -0.39, a P/BV ratio of 0.53 and in the last 12 months the Company did not pay dividends.
The Company is traded internationally through the ticker TLRY.
